Status:
RECRUITING
Immunogenomic Dynamics and Biomarkers in Patients With Hepatocellular Carcinoma Receiving Immunotherapy
Lead Sponsor:
Asan Medical Center
Conditions:
Hepatocellular Carcinoma
Liver Cancer
Eligibility:
All Genders
19+ years
Brief Summary
1. Research purpose To perform genomic and immune profiling analysis on blood and tissue samples obtained from blood sampling and tumor biopsy in patients with advanced hepatocellular carcinoma with i...
Detailed Description
This study is designed to perform comprehensive genomic and immune profiling in patients with advanced hepatocellular carcinoma (HCC) undergoing immuno-oncology (IO) treatment. The objective is to inv...
Eligibility Criteria
Inclusion
- Patients with histologically confirmed HCC,
- Patients with histologically confirmed locally advanced, recurrent or metastatic HCC, which was judged not to be eligible for surgical resection, liver transplantation or radiofrequency ablation
- Patients who will receive immuno-oncology treatment
Exclusion
- Patients with histologically confirmed fibrolamellar type HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC
- Patients with concurrent other malignancy
- Patients who are candidates for local curative treatments such as hepatic resection, liver transplantation, or radiofrequency ablation
- Patients who have a possibility of confusion in the results of the clinical research
Key Trial Info
Start Date :
September 28 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT07186010
Start Date
September 28 2020
End Date
December 31 2026
Last Update
September 22 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Asan Medical Center
Seoul, Song-pa, South Korea, 05505